Skip to main content

Advertisement

SpringerLink
Log in

Hepatic encephalopathy: A review of its pathophysiology and treatment

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Hepatic encephalopathy (HE) is a broad spectrum of neuropsychiatric manifestations usually affecting individuals with end-stage liver disease. The presence of HE is a poor prognostic sign, with 1-year mortality rates of almost 60%. There is much debate about the underlying mechanisms that result in this syndrome; however, elevated plasma and central nervous system ammonia levels are considered key factors in its pathogenesis. Initial evaluation of the patient presenting with overt HE should include a careful search for predisposing factors, including underlying infection, gastrointestinal (GI) bleeding, electrolyte disturbances, hepatocellular carcinoma, dehydration, hypotension, and excessive use of benzodiazepines, psychoactive drugs, or alcohol. The mainstay of treatment for many years has been nonabsorbable disaccharides, particularly lactulose. Alternative treatments, which usually are second line in patients who do not respond to lactulose, include zinc, antibiotics (neomycin, metronidazole, and rifaximin), ornithine aspartate, sodium benzoate, probiotics, and surgical intervention. Accepted treatments for HE are associated with significant unpleasant side effects, including diarrhea, renal failure, neuropathy, and other GI disturbance. Newer therapies are still in development, and most are awaiting human trials in order to confirm their benefit. These include manganese chelators, L-carnitine, N-methyl-D-aspartate receptor antagonists, blood purification dialysis system, and an intravenous combination of sodium benzoate and phenylacetate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gitlin N: Hepatic encephalopathy. In Hepatology: A Textbook of Liver Disease, edn 3, vol 1. Edited by Zakim D, Boyer TD. Philadelphia: WB Saunders; 1996:605–617.

    Google Scholar 

  2. Ferenci P, Lockwood A, Mullen K, et al.: Hepatic encephalopathy —definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716–721.

    Article  PubMed  Google Scholar 

  3. Blei A, Cordoba J, Practice Parameters Committee of the American College of Gastroenterology: Hepatic encephalopathy. Am J Gastroenterol 2001, 96:1968–1976.

    Article  PubMed  CAS  Google Scholar 

  4. Mendler M, Donovan J, Blei A: Central nervous system and pulmonary complications of end-stage liver diseases. In Textbook of Gastroenterology, edn 4, vol 2. Edited by Yamada J, Alpers D, Kaplowitz N, et al. Philadelphia: Lippincott Williams & Wilkins; 2003:2445–2467.

    Google Scholar 

  5. Amodio P, Montagnese S, Gatta A, et al.: Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004, 19:253–265.

    Article  PubMed  Google Scholar 

  6. Bustamante J, Rimola A, Ventura PJ, et al.: Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999, 30:890–895.

    Article  PubMed  CAS  Google Scholar 

  7. Shawcross DL, Damink SW, Butterworth RF, Jalan R: Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005, 20:169–179.

    Article  PubMed  CAS  Google Scholar 

  8. Romero-Gomez M, Ramos-Guerrero R, Grande L, et al.: Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004, 41:49–54.

    Article  PubMed  CAS  Google Scholar 

  9. Lockwood AH: Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis 2004, 19:345–354.

    Article  PubMed  CAS  Google Scholar 

  10. Ahl B, Weissenborn K, van den Hoff J, et al.: Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology 2004, 40:73–79.

    Article  PubMed  CAS  Google Scholar 

  11. O’Carroll RE, Hayes PC, Ebmeier KP, et al.: Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 1991, 337:1250–1253.

    Article  PubMed  CAS  Google Scholar 

  12. Ong JP, Aggarawal A, Krieger D, et al.: Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003, 114:188–193.

    Article  PubMed  CAS  Google Scholar 

  13. Kundra A, Jain A, Banga A, et al.: Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial pressure. Clin Biochem 2005, 38:696–699.

    Article  PubMed  CAS  Google Scholar 

  14. Oritz M, Jacas C, Cordoba J: Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005, 42(Suppl 1):S45-S53. This article provides valuable information about minimal HE, an entity that is often underrecognized and undertreated.

    Article  Google Scholar 

  15. Cordoba J, Lopez-Hellin J, Planas M, et al.: Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004, 41:38–43. Randomized study that demonstrates that protein restriction does not offer any benefits in patients with HE.

    Article  PubMed  CAS  Google Scholar 

  16. Plauth M, Merli M, Kondrup J, et al.: ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997, 16:43–55.

    Article  PubMed  CAS  Google Scholar 

  17. PINC (Policentrica Italiana Nutrizione Cirrosi), Merli M, Riggio O, Dally L: Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996, 23:1041–1046.

    Article  PubMed  CAS  Google Scholar 

  18. Riordan SM, Williams R: Treatment of hepatic encephalopathy. N Engl J Med 1997, 337:473–479.

    Article  PubMed  CAS  Google Scholar 

  19. Gluud C: Branched-chain amino acids for hepatic encephalopathy? Hepatology 1991, 13:812–813.

    Article  PubMed  CAS  Google Scholar 

  20. DerSimonian R: Parenteral nutrition with branchedchain amino acids in hepatic encephalopathy: meta analysis. Hepatology 1990, 11:1083–1084.

    Article  PubMed  CAS  Google Scholar 

  21. Grungreiff K: Zinc in liver disease. J Trace Elem Exp Med 2002, 15:67–78.

    Article  CAS  Google Scholar 

  22. Marchesini G, Fabbri A, Bianchi G, et al.: Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996, 23:1084–1092.

    Article  PubMed  CAS  Google Scholar 

  23. Riggio O, Ariosto F, Merli M, et al.: Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991, 36:1204–1208.

    Article  PubMed  CAS  Google Scholar 

  24. Morgan MY, Hawley KE: Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind randomized trial. Hepatology 1987, 7:1278–1284.

    Article  PubMed  CAS  Google Scholar 

  25. Blanc P, Daures JP, Rouillon JM, et al.: Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1991, 15:222–228.

    Article  Google Scholar 

  26. Uribe M, Marquez MA, Garcia-Ramos G, et al.: Treatment of portal-systemic encephalopathy with lactose in lactase-deficient patients. Dig Dis Sci 1980, 25:924–928.

    Article  PubMed  CAS  Google Scholar 

  27. Watanabe A, Sakai T, Sato S, et al.: Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997, 26:1410–1414.

    Article  PubMed  CAS  Google Scholar 

  28. Shawcross D, Jalan R: Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005, 365:431–433.

    PubMed  Google Scholar 

  29. Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004, 328:1046.

    Article  PubMed  CAS  Google Scholar 

  30. The Uncommon Drugstore. Available at: http://www.drugstore. com. Accessed June 2006.

  31. Vasconez C, Elizade I, Llach J, et al.: Helicobacter pylori, hyperammonamia and subclinical portosystemic encephalopathy: effects of eradication. J Hepatol 1999, 30:260–264.

    Article  PubMed  CAS  Google Scholar 

  32. Capocaccia L, Riggio O: Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: Do they enhance each other? Hepatology 1990, 12:368–370.

    Article  PubMed  CAS  Google Scholar 

  33. Morgan MH, Read AE, Speller DC: Treatment of hepatic encephalopathy with metronidazole. Gut 1982, 23:1–7.

    PubMed  CAS  Google Scholar 

  34. Mas A, Rodes J, Sunyer L, et al.: Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, doubledummy, controlled clinical trial. J Hepatol 2003, 38:51–58.

    Article  PubMed  CAS  Google Scholar 

  35. Gentile S, Guarino G, Romano M, et al.: A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005, 3:184–191.

    Article  PubMed  CAS  Google Scholar 

  36. Barbaro G, Di Lorenzo G, Soldini M: Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998, 28:374–378.

    Article  PubMed  CAS  Google Scholar 

  37. Grimm G, Katzenschlager R, Schneeweiss B, et al.: Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988, 332:1392–1394.

    Article  Google Scholar 

  38. Stauch S, Kircheis G, Adler G, et al.: Oral L-ornithine-Laspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998, 28:856–864.

    Article  PubMed  CAS  Google Scholar 

  39. Kircheis G, Nilius R, Held C, et al.: Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25:1351–1360.

    Article  PubMed  CAS  Google Scholar 

  40. Sushma S, Dasarthy S, Tandon RK, et al.: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16:138–144.

    Article  PubMed  CAS  Google Scholar 

  41. Mendenhall CL, Rouster S, Marshall L, et al.: A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986, 81:540–543.

    PubMed  CAS  Google Scholar 

  42. Loguercio C, Abbiati R, Rinaldi M, et al.: Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1–2 hepatic encephalopathy. J Hepatol 1995, 23:39–46.

    Article  PubMed  CAS  Google Scholar 

  43. Liu Q, Duan ZP, Ha DK, et al.: Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441–1449.

    Article  PubMed  Google Scholar 

  44. Madoff DG, Wallace MJ, Ahrar K, et al.: TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. Radiographics 2004, 24:21–23.

    Article  PubMed  Google Scholar 

  45. Yoshida H, Mamada Y, Taniai N, et al.: Long-term results of partial splenic embolization as supplemental treatment for portal-systemic encephalopathy. Am J Gastroenterol 2005, 100:43–44.

    Article  PubMed  Google Scholar 

  46. Solomou E, Velissaris D, Polychronopoulos P, et al.: Quantitative evaluation of magnetic resonance imaging abnormalities in subclinical hepatic encephalopathy. Hepatogastroenterology 2005, 52:203–207.

    PubMed  CAS  Google Scholar 

  47. Therrien G, Rose C, Butterworth J, et al.: Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology 1997, 25:551–556.

    Article  PubMed  CAS  Google Scholar 

  48. Malaguarnera M, Pistone G, Elvira R, et al.: Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005, 11:7197–7202.

    PubMed  CAS  Google Scholar 

  49. Monfort P, Munoz MD, Felipo V: Molecular mechanisms of the alterations in NMDA receptor-dependent longterm potentiation in hyperammonemia. Metab Brain Dis 2005, 20:265–274.

    Article  PubMed  CAS  Google Scholar 

  50. Vogels B, Maas M, Daalhuisen J, et al.: Memantine, a non-competitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997, 25:820–827.

    Article  PubMed  CAS  Google Scholar 

  51. Izumi Y, Izumi M, Matsukawa M, et al.: Ammoniamediated LTP inhibition: effects of NMDA receptor antagonists and L-carnitine. Neurobiol Dis 2005, 20:615–624.

    Article  PubMed  CAS  Google Scholar 

  52. Hassanein T, Tofteng F, Brown R, Jr, et al.: Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: a prospective, controlled, randomized multicenter trial [abstract]. Hepatology 2004, 4(Suppl 1):726A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Alabama at Birmingham, 1530 Third Avenue South, MCLM 262A, 35294-0005, Birmingham, AL, USA

    Brendan M. McGuire MD, MS

Authors
  1. Nader Dbouk MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brendan M. McGuire MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dbouk, N., McGuire, B.M. Hepatic encephalopathy: A review of its pathophysiology and treatment. Curr Treat Options Gastro 9, 464–474 (2006). https://doi.org/10.1007/s11938-006-0003-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-006-0003-x

Keywords

Search

Navigation